Bradford Amman - Vivos Therapeutics Treasurer CFO
| VVOS Stock | USD 3.93 0.31 7.31% |
Insider
Bradford Amman is Treasurer CFO of Vivos Therapeutics
| Age | 63 |
| Address | 7921 Southpark Plaza, Littleton, CO, United States, 80120 |
| Phone | 844 672 4357 |
| Web | https://www.vivos.com |
Bradford Amman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Bradford Amman against Vivos Therapeutics stock is an integral part of due diligence when investing in Vivos Therapeutics. Bradford Amman insider activity provides valuable insight into whether Vivos Therapeutics is net buyers or sellers over its current business cycle. Note, Vivos Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Vivos Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Bradford Amman over two months ago Acquisition by Bradford Amman of 149533 shares of Vivos Therapeutics at 2.64 subject to Rule 16b-3 |
Vivos Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.57) % which means that it has lost $0.57 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8496) %, meaning that it created substantial loss on money invested by shareholders. Vivos Therapeutics' management efficiency ratios could be used to measure how well Vivos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.72 in 2025. Return On Capital Employed is likely to gain to -5.49 in 2025. At this time, Vivos Therapeutics' Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 27 M in 2025, whereas Total Current Assets are likely to drop slightly above 2.1 M in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| Mark Feinberg | Bluejay Diagnostics | N/A | |
| Kevin Vance | Bluejay Diagnostics | 67 | |
| Jennifer Ernst | Tivic Health Systems | 57 | |
| Danielle Watson | Heart Test Laboratories | 43 | |
| William MD | Nuwellis | N/A | |
| John Wilson | Rapid Micro Biosystems | 57 | |
| Veronica Cai | Tivic Health Systems | 48 | |
| Victoria Vezina | Rapid Micro Biosystems | 56 | |
| Kenneth CPA | Bluejay Diagnostics | 44 | |
| Ryan Sabia | Tivic Health Systems | 37 | |
| Rob Scott | Nuwellis | N/A | |
| M Harrison | NanoVibronix | N/A | |
| Harold MD | NanoVibronix | 71 | |
| Mark MD | Bluejay Diagnostics | N/A | |
| Blake Gurfein | Tivic Health Systems | 41 | |
| Sandra Eayrs | Nuwellis | N/A | |
| Shunichi Kuroda | Bone Biologics Corp | N/A | |
| Jason Cook | Bluejay Diagnostics | 43 | |
| Laurent Duhoux | Nuwellis | N/A | |
| Jonathan Paris | Rapid Micro Biosystems | 48 | |
| Sanjay Ahuja | Tivic Health Systems | N/A | |
Management Performance
| Return On Equity | -2.85 | ||||
| Return On Asset | -0.57 |
Vivos Therapeutics Leadership Team
Elected by the shareholders, the Vivos Therapeutics' board of directors comprises two types of representatives: Vivos Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vivos. The board's role is to monitor Vivos Therapeutics' management team and ensure that shareholders' interests are well served. Vivos Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vivos Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| RaeAnn Byrnes, CoFounder Services | ||
| Kirk Huntsman, Chairman CoFounder | ||
| Julie Gannon, Chief Relations | ||
| Nicholas DeGennaro, Senior Division | ||
| John Ballard, Senior Technology | ||
| Ruth Hembree, Senior Services | ||
| Todd Huntsman, CoFounder Technology | ||
| Stephanie Huebner, Senior Integration | ||
| Susan McCullough, CoFounder Operations | ||
| Bradford Amman, Treasurer CFO |
Vivos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vivos Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.85 | ||||
| Return On Asset | -0.57 | ||||
| Profit Margin | (0.86) % | ||||
| Operating Margin | (0.48) % | ||||
| Current Valuation | 18.48 M | ||||
| Shares Outstanding | 5.89 M | ||||
| Shares Owned By Insiders | 1.51 % | ||||
| Shares Owned By Institutions | 13.72 % | ||||
| Number Of Shares Shorted | 272.99 K | ||||
| Price To Book | 3.02 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vivos Stock Analysis
When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.